Cerenome, Inc. (CNSY)
- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $1.64
- As of
Kresmion compiles this page from CNSY's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
CERENOME, INC. (CNSY): 1 institutional manager tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-10-02.
See the full CNSY dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for CNSY on one page. Preview it with sample data, then open it live with a free account.
Preview the CNSY dossierActive signals for CNSY
- mediumEarnings below estimates
Q2-2026: Missed consensus by 41.1%, EPS $-1.31 vs $-0.9282 estimate
FREE, NO ACCOUNT
Every signal on CNSY, as it fires
New filings, 13F moves and cross asset signals on CNSY land in the record first.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in CNSY (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| CITADEL ADVISORS LLCCUSIP 72941H806 · 2026Q2 | $112K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, CNSY
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
CNSY against its peers
CNSY's operating margin of -293.5% ranks in the 94th percentile of 7 Biotechnology sub-industry peers, fiscal periods ending between 2025-06-30 and 2025-12-31.
| Metric | CNSY | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 5.2M USD | 509589 USD | 75 | 9 |
| Operating margin | -293.5% | -4024.9% | 94 | 7 |
| Net margin | -429.4% | -850.7% | 61 | 8 |
| Return on equity | -560.2% | -65.5% | 3 | 14 |
Peers (16): IBO, MCRB, NXTC, RNAZ, ABVC, ATOS, BCTX, MGX, GNTA, GRDX, CNTX, BRNS, ALGS, IMMP, SGMOQ, BYSI. Left out: TTIPF (no annual filing), IGC (no annual filing), ZIVO (period gap), EVAX (no annual filing), MDNAF (no annual filing), RLFTY (no annual filing), PLRZ (no annual filing), BSEM (no annual filing), SEOVF (no annual filing). Fiscal periods ending between 2025-06-30 and 2025-12-31. Every figure is one full fiscal year read from one annual filing (CNSY: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow CNSY on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to CNSY for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.